Product Theater at CAP 2021

September 27, 2021, 9:45AM-10:45AM PT

Join us at CAP to learn more about a Pathologist’s perspective on CGP and how the Oncotype MAP Pan-Cancer Tissue test has been used to guide therapy selection in NSCLC in the webinar "What Can We Learn from NSCLC? A Pathologist’s Perspective on Using Comprehensive Genomic Profiling to Enhance Patient Care".

UroCareLive Webinar

Available Now On-Demand

Drs. Sellinger and Shore discuss “Incorporating Genomic Profiling and Biomarker Testing in Clinical Practice” using the Oncotype tests for advanced prostate cancer patients.

New Cut Point for Unfavorable Intermediate and High-Risk Patients

Oncotype DX Genomic Prostate Score

The Oncotype DX GPS assay stratifies unfavorable intermediate and high-risk patients into two distinct groups with highly differing long-term outcomes.

Expanded Medicare Coverage

Oncotype DX Genomic Prostate Score

The Oncotype DX Genomic Prostate Score assay is fully covered by Medicare for localized prostate cancer patients.

Oncotype MAP™ Pan-Cancer Tissue Test Webinar

What Can We Learn from NSCLC?

Learn how NGS-based comprehensive genomic profiling has enhanced patient care through real-world NSCLC case studies, presented by Drs. Edgardo Santos, Snehal Thakkar, and Jean-Paul De La O.
Making cancer care smarter.®